



COLLABORATION FOR COMMON STANDARDS


Karell G. Pellé, PhD, Senior Scientist

Clinical Decision Support Systems: Features, Future and Fostering Collaboration, 8 February 2023



# FIND HAS BEEN WORKING WITH PARTNERS FOR 20 YEARS

# DRIVING INNOVATION AND DELIVERY OF DIAGNOSTICS



### TPPS ADDRESS PRIORITY HEALTH NEEDS IN LMICS



# PLOS ONE

⑥ OPEN ACCESS № PEER-REVIEWED

RESEARCH ARTICLE

Target Product Profile for a mobile app to read rapid diagnostic tests to strengthen infectious disease surveillance

Riqveda Kadam , Wallace White, Nicholas Banks, Zachary Katz, Sabine Dittrich, Cassandra Kelly-Cirino

Published: January 29, 2020 • https://doi.org/10.1371/journal.pone.0228311

Research

BMJ Global Health

Redefining typhoid diagnosis: what would an improved test need to look like?

Richard G Mather <sup>1,2</sup> Heidi Hopkins <sup>1,2</sup> Christopher M Parry <sup>1,2</sup> Sabine Dittrich <sup>1,5</sup> Abine Dittrich <sup>1,5</sup>



#### **TARGET PRODUCT PROFILE 5:**

#### Rapid test for diagnosis of malaria and screening for human trypanosomiasis (HAT)

This target product profile (TPP) includes 31 test features. These features re requirements or specifications of the diagnostic tool to be developed. For each f desired (optimal) target and a minimally accepted target are defined in a table.

To facilitate consensus building around this TPP, a Delphi-like survey process v each TPP feature, an agreement percentage was calculated. Agreement was sco ranging from 1 to 5 (1-disagree, 2-somewhat disagree, 3-neither agree nor disagree, agree, 5-fully agree). Participants were asked to provide comments when they did a statement (that is, when they scored a feature at 3 or lower).



Development of a target product profile for a point-of-care cardiometabolic device


Beatrice Vetter, David Beran, [...], and Sigiriya Aebischer

Perone

# **Meeting Report**


High-priority target product profiles for new tuberculosis diagnostics: report of a consensus meeting













## BUILDING MULTIDISCIPLINARY CONSENSUS FOR EVIDENCE-BASED CDSS






haracteristic ntended use arget Population etting grageted End User Igorithm Access Igorithm Content Igorithm Treatment Recommendations ompatible Point of Care Tools egulated Toolkit Components ompatible Devices ompatible Operating Systems ontent Transparency uality control Igorithm Validation dachine Learning OC Data Inputs isease Likelihood OC Training	Min 96% 96% 100% 96% 96% 91% 91% 83% 87% 91% 91%	Opt 96% 96% 96% 100% 96% 91% 91% 87% 87% 87% 91% 91%	96% 96% 96% 100% 196% 196% 196% 191% 1834 1874 1874 1918	100% 75% 50% 25% 0%  96%  96%  96%  96%  100%  96%  96%  96%  95%  95%  95%  97%  87%  87%  87%
arget Population etting argeted End User Igorithm Access Igorithm Content Igorithm Content Igorithm Teatment Recommendations ompatible Point of Care Tools egulated Toolkit Components ompatible Devices ompatible Operating Systems ontent Transparency Iuality control Igorithm Validation Aachine Learning OC Data Inputs isease Likelihood	96% 96% 100% 96% 96% 91% 91% 83% 87% 91% 91%	96% 96% 100% 96% 96% 91% 87% 87% 87% 91%	96% 96% 100% 196% 196% 191% 1918 1918 1939 1839 1879 1879	96% 96% 100% 96% 96% 191% 191% 87% 87%
etting largeted End User lgorithm Access lgorithm Content lgorithm Treatment Recommendations ompatible Point of Care Tools egulated Toolkit Components ompatible Devices ompatible Devices ompatible Operating Systems ontent Transparency luality control lgorithm Validation dachine Learning OC Data Inputs isease Likelihood	96% 100% 96% 96% 91% 91% 83% 87% 91% 91%	96% 100% 96% 96% 91% 91% 87% 87% 91%	96% 300% 96% 96% 95% 91% 91% 83% 87% 87%	96% 100% 96% 95% 91% 91% 87% 87%
argeted End User Igorithm Access Igorithm Content Igorithm Treatment Recommendations ompatible Point of Care Tools egulated Toolkit Components ompatible Devices ompatible Operating Systems ontent Transparency ugality control Igorithm Validation dachine Learning OC Data Inputs isease Likelihood	100% 96% 96% 91% 91% 83% 87% 91% 91%	100% 96% 96% 91% 91% 87% 87% 87% 91%	100% 196% 196% 196% 191% 191% 191% 191% 191% 191% 191%	100%  96%   96%   91%   91%   87%   87%
Igorithm Access Igorithm Content Igorithm Textment Recommendations ompatible Point of Care Tools egulated Toolkit Components ompatible Devices ompatible Devices ompatible Operating Systems ontent Transparency utuality control Igorithm Validation dachine Learning OC Data Inputs isease Likelihood	96% 96% 91% 91% 83% 87% 91% 91%	96% 96% 91% 91% 87% 87% 87% 91%	96% 96% 96% 91% 91% 83% 87%	96% 95% 91% 91% 87% 87%
Igorithm Content Igorithm Treatment Recommendations ompatible Point of Care Tools egulated Toolkit Components ompatible Devices ompatible Operating Systems ontent Transparency tuality control Igorithm Validation dachine Learning OC Data Inputs isease Likelihood	96% 96% 91% 91% 83% 87% 91% 91%	96% 91% 91% 87% 87% 87% 91%	96% 96% 91% 91% 83% 87%	96% 91% 91% 87% 87%
Igorithm Treatment Recommendations ompatible Point of Care Tools egulated Toolkit Components ompatible Devices ompatible Devices ompatible Operating Systems ontent Transparency uality control Igorithm Validation dachine Learning OC Data Inputs sisease Likelihood	96% 91% 91% 83% 87% 87% 91% 91%	91% 91% 87% 87% 87% 91% 91%	96% 91% 91% 83% 87%	91% 91% 87% 87%
ompatible Point of Care Tools egulated Toolkit Components ompatible Devices ompatible Operating Systems ontent Transparency utuality control lgorithm Validation dachine Learning OC Data Inputs isease Likelihood	91% 91% 83% 87% 87% 91% 91%	91% 87% 87% 87% 91% 91%	91% 91% 83% 87% 87%	91% 87% 87% 87%
egulated Toolkit Components ompatible Devices ompatible Operating Systems ontent Transparency tuality control lgorithm Validation dachine Learning OC Data Inputs isease Likelihood	91% 83% 87% 87% 91% 91%	87% 87% 87% 91% 91%	91% 83% 87% 87%	87% 87%
ompatible Devices ompatible Operating Systems ontent Transparency tuality control algorithm Validation dachine Learning OC Data Inputs sisease Likelihood	83% 87% 87% 91% 91% 96%	87% 87% 91% 91%	83% 87% 87%	87% 87%
ompatible Operating Systems ontent Transparency usulity control Igorithm Validation dachine Learning OC Data Inputs isease Likelihood	87% 87% 91% 91% 96%	87% 91% 91%	87%	87%
ontent Transparency uuality control Igorithm Validation Machine Learning OC Data Inputs iisease Likelihood	87% 91% 91% 96%	91% 91%	87%	
uality control Igorithm Validation dachine Learning OC Data Inputs visease Likelihood	91% 91% 96%	91%		
lgorithm Validation fachine Learning OC Data Inputs iisease Likelihood	91% 96%			91%
fachine Learning OC Data Inputs Iisease Likelihood	96%	21/0	91%	91%
OC Data Inputs isease Likelihood		87%	96%	87%
isease Likelihood	0//0	87%	87%	87%
	83%	87%	83%	87%
	87%	87%	87%	87%
vstem Validation	83%	83%	83%	83%
ystem Access (public API)	91%	96%	91%	96%
ontext Configuration	87%	91%	87%	91%
ustomisation		100%	100%	100%
Iser Access Rights	100%	96%	100%	
xpert Support	87%	87%	87%	96%
pp Training	91%	91%	91%	
nternet Availability	96%	96%		91%
linical Data Entry	87%	96%	96%	96%
atient Management Recommendation		100%	87%	96%
lavigation	96%	83%	96%	100%
Vorkflow	83%	83%	96%	83%
ask Management	87%	91%	83%	83%
ollow up	100%	96%	87%	91%
ystem Malfunction Protection	96%	96%	100%	96%
	91%	91%	96%	96%
calability		100%	91%	91%
pdates and Versioning lata Capture	83%	91%	100%	100%
			83%	91%
ata Validation	96% 96%	96% 96%	96%	96%
ata Ownership	96%	96%	96%	96%
ata Storage ata Recovery		100%	91%	91%
ata Recovery			100%	100%
	87%	87%	87%	87%
				100%
				96%
				96%
				91%
				87%
verage	91%	91%	91%	91%
	Legeno	d:	■ Fully agree	
	MARCH STREET,			
			■ Mostly disagree	
al al	ta Reporting ta Provenance ta Dictionary ta Security & Privacy curement Models erage	ta Provenance 96% ta Dictionary 91% ta Dictionary 91% ta Security 87% privacy 87% privacy 91% prage 91% prage 91% Legent	ta Provenance 96% 96% ta Dictionary 91% 96% ta Security & Privacy 87% 91% curement Models 91% 87%	ta Provenance 96% 96% 96% 1 96% 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1

Final CDSS expert agreement for TPP characteristics\*




# A COLLABORATIVE ECOSYSTEM TO MAXIMIZE LONG TERM IMPACT



## THANK YOU FOR YOUR ATTENTION





alongside significant financial contributions from our private sector partners





































































